Zurcher Kantonalbank Zurich Cantonalbank Raises Position in Hologic, Inc. (NASDAQ:HOLX)

Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 364,776 shares of the medical equipment provider’s stock after acquiring an additional 10,049 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Hologic were worth $26,297,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. General Partner Inc. purchased a new position in Hologic during the fourth quarter valued at $26,000. Groupama Asset Managment raised its stake in shares of Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 2,999 shares during the period. Venturi Wealth Management LLC lifted its position in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares in the last quarter. First Horizon Advisors Inc. grew its stake in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares during the period. Finally, Smartleaf Asset Management LLC increased its holdings in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 159 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Down 4.6 %

Shares of NASDAQ:HOLX opened at $62.59 on Wednesday. The company has a market cap of $14.04 billion, a price-to-earnings ratio of 19.74, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 12 month low of $61.70 and a 12 month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a 50-day moving average price of $67.87 and a 200 day moving average price of $75.04.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on HOLX shares. Wolfe Research started coverage on shares of Hologic in a report on Friday, December 13th. They set a “peer perform” rating on the stock. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a research report on Monday, February 3rd. Royal Bank of Canada dropped their target price on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday, February 6th. Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Finally, Morgan Stanley dropped their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic currently has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.